Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Royalty Pharma

2 Hot Growth Stocks Poised for Gains of Up to 370%, According to Wall Street

These biotech companies’ strategic advancements are setting them up for long-term success.

Royalty Pharma Getting Closer To Key Technical Measure

Royalty Pharma Getting Closer To Key Technical Measure

Royalty Pharma shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

Cytokinetics' Wild Ride: CEO Defends Deal That Rattled Wall Street

Cytokinetics stock plummeted on a Royalty Pharma deal for three of its heart disease drugs. Here's what CEO Robert Blum says investors missed.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Agios Breaks Out On 'Buffed Up' Financials After Inking Massive Brain Cancer Deal

Agios agreed Tuesday to sell its 15% royalty in a brain cancer drug for $905 million upfront. Agios stock broke out at the open.

Investors Business Daily

Warren Buffett’s portfolio: Here are the stocks Berkshire Hathaway is buying or selling

Warren Buffett is arguably the world’s most famous investor, and his investment moves are closely followed. Each quarter, the company he runs, Berkshire Hathaway, discloses its current holdings to shareholders.

Tribune News Service

This Analyst Thinks Blueprint Medicines' Non-Dilutive Funding 'Deflates M&A Speculation'

Today Blueprint Medicines Corp (NASDAQ:BPMC) announced strategic financing agreements with Sixth Street and Royalty Pharma Plc (NASDAQ:RPRX) for up to $1.25 billion, including $575 million upfront upon deal closure. SVB Securities thinks the terms of the deals are fairly valued on the Sixth Street portion and favorable for Blueprint Medicines on the Royalty Pharma portion. "In addition,…

Expert Ratings for Royalty Pharma

Royalty Pharma (NASDAQ:RPRX) has observed the following analyst ratings within the last quarter:

inkl

Read news from The Economist, FT, and more,
with one subscription

Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2022

Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2022

Royalty Pharma Earnings Perspective: Return On Capital Employed

Royalty Pharma Earnings Perspective: Return On Capital Employed

Pulled from Benzinga Pro data, Royalty Pharma (NASDAQ:RPRX) posted Q1 earnings of $128.08 million, an increase from Q4 of 138.64%. Sales dropped to $562.00 million, a 2.43% decrease between quarters.

Executives Sell Around $325M Of 3 Stocks

Executives Sell Around $325M Of 3 Stocks

Gold futures traded higher this morning on Tuesday. Investors, meanwhile, focused on some notable insider trades.

Warren Buffett’s portfolio: Here are the stocks Berkshire Hathaway is buying or selling

Warren Buffett is arguably the world’s most famous investor, and his investment moves are closely followed. Each quarter, the company he runs, Berkshire Hathaway, discloses its current holdings to shareholders.

Tribune News Service

Benzinga's Top Ratings Upgrades, Downgrades For May 13, 2022

Benzinga's Top Ratings Upgrades, Downgrades For May 13, 2022

Expert Ratings for Royalty Pharma

Expert Ratings for Royalty Pharma

Analysts have provided the following ratings for Royalty Pharma (NASDAQ:RPRX) within the last quarter:

Royalty Pharma: Q1 Earnings Insights

Royalty Pharma: Q1 Earnings Insights

Royalty Pharma (NASDAQ:RPRX) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Get all your
news in one place.

100’s of premium titles.
One news app.

Recap: Royalty Pharma Q1 Earnings

Royalty Pharma (NASDAQ:RPRX) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

How To Attend Royalty Pharma Q1 2022 Earnings Conference Call

Royalty Pharma (NASDAQ:RPRX) will host a conference call at 08:00 AM ET on May 5, 2022, to discuss Q1 2022 earnings results. How to Attend Royalty Pharma (RPRX) Conference Call Follow this link to access the live webcast.

Benzinga's Top Ratings Upgrades, Downgrades For April 27, 2022

Read Here Why Did BioCryst Stopped Enrollment In BCX9930 Studies In Rare Blood Disorder

BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) has paused enrollment in clinical trials with BCX9930 as the Company investigates elevated serum creatinine levels seen in some patients. The Company will not enroll new patients in the REDEEM-1, REDEEM-2, or RENEW clinical trials during the investigation. Patients currently enrolled in the trials are continuing on the study…

Get all your
news in one place.

100’s of premium titles.
One news app.

Hopeful Golden Cross Forms On Royalty Pharma's Chart

If history is any guide, there may be good fortune ahead for shares of Royalty Pharma (NASDAQ:RPRX). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock.

Looking Into Royalty Pharma's Return On Capital Employed

According to Benzinga Pro, during Q4, Royalty Pharma (NASDAQ:RPRX) earned $53.67 million, a 75.8% increase from the preceding quarter. Royalty Pharma's sales decreased to $576.00 million, a 1.67% change since Q3.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Activision Blizzard

Berkshire Hathaway

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play